AR125021A1 - RNAi COMPOSITIONS AGAINST THE ANGIOPOYETIN-LIKE GENE 3 (ANGPTL3) AND THEIR METHODS OF USE - Google Patents
RNAi COMPOSITIONS AGAINST THE ANGIOPOYETIN-LIKE GENE 3 (ANGPTL3) AND THEIR METHODS OF USEInfo
- Publication number
- AR125021A1 AR125021A1 ARP220100472A ARP220100472A AR125021A1 AR 125021 A1 AR125021 A1 AR 125021A1 AR P220100472 A ARP220100472 A AR P220100472A AR P220100472 A ARP220100472 A AR P220100472A AR 125021 A1 AR125021 A1 AR 125021A1
- Authority
- AR
- Argentina
- Prior art keywords
- angptl3
- shrna
- agent
- gene
- cell
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 108091030071 RNAI Proteins 0.000 title 1
- 230000009368 gene silencing by RNA Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 101000693085 Homo sapiens Angiopoietin-related protein 3 Proteins 0.000 abstract 8
- 108091027967 Small hairpin RNA Proteins 0.000 abstract 8
- 239000003795 chemical substances by application Substances 0.000 abstract 8
- 239000004055 small Interfering RNA Substances 0.000 abstract 8
- 102100025668 Angiopoietin-related protein 3 Human genes 0.000 abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 abstract 5
- 230000002401 inhibitory effect Effects 0.000 abstract 4
- 230000000692 anti-sense effect Effects 0.000 abstract 3
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 108091081021 Sense strand Proteins 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 229920002477 rna polymer Polymers 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Un agente de ácido ribonucleico de hebra doble (ARNhd) para inhibir la expresión del gen Similar a Angiopoyetina 3 (ANGPTL3) en una célula, caracterizado porque el agente de ARNhd comprende una hebra sentido y una hebra antisentido que forman una región de hebra doble, en donde la hebra antisentido comprende una región de complementariedad con un ARNm que codifica para ANGPTL3, y en donde la región de complementariedad comprende por lo menos 15 nucleótidos consecutivos que difieren en no más de 3 nucleótidos con respecto a una cualquiera de las secuencias nucleotídicas antisentido de una cualquiera de las Tablas 2 - 3 y 7 - 8. Reivindicación 73: Una célula caracterizada porque contiene el agente de ARNhd de cualquiera de las reivindicaciones 1 a 72. Reivindicación 74: Una composición farmacéutica para inhibir la expresión de un gen que codifica para la proteína Similar a Angiopoyetina 3 (ANGPTL3) caracterizada porque comprende el agente de ARNhd de cualquiera de las reivindicaciones 1 a 72. Reivindicación 80: Un método para inhibir la expresión de un gen Similar a Angiopoyetina 3 (ANGPTL3) en una célula, caracterizado porque el método comprende el paso de poner en contacto la célula con el agente de ARNhd de cualquiera de las reivindicaciones 1 a 72, o la composición farmacéutica de cualquiera de las reivindicaciones 74 a 79, inhibiendo de esa manera la expresión del gen ANGPTL3 en la célula. Reivindicación 100: Un kit caracterizado porque comprende el agente de ARNhd de cualquiera de las reivindicaciones 1 a 72 o la composición farmacéutica de cualquiera de las reivindicaciones 74 a 79. Reivindicación 101: Un vial caracterizado porque comprende el agente de ARNhd de cualquiera de las reivindicaciones 1 a 72 o la composición farmacéutica de cualquiera de las reivindicaciones 74 a 79. Reivindicación 102: Una jeringa caracterizada porque comprende el agente de ARNhd de cualquiera de las reivindicaciones 1 a 72 o la composición farmacéutica de cualquiera de las reivindicaciones 74 a 79.Claim 1: A double-stranded ribonucleic acid (shRNA) agent for inhibiting the expression of the Angiopoietin-Like 3 (ANGPTL3) gene in a cell, characterized in that the shRNA agent comprises a sense strand and an antisense strand that form a region of double stranded, wherein the antisense strand comprises a region of complementarity to an mRNA encoding ANGPTL3, and wherein the region of complementarity comprises at least 15 consecutive nucleotides that differ by no more than 3 nucleotides from any one of the antisense nucleotide sequences from any one of Tables 2-3 and 7-8. Claim 73: A cell characterized in that it contains the shRNA agent of any of claims 1 to 72. Claim 74: A pharmaceutical composition for inhibiting the expression of a gene encoding the protein Angiopoietin-Like 3 (ANGPTL3) characterized in that it comprises the shRNA agent of any of claims 1 to 72. Claim 80: A method of inhibiting the expression of an Angiopoietin-Like 3 (ANGPTL3) gene in a cell, characterized in that the method comprises the step of contacting the cell with the shRNA agent of any of claims 1 to 72, or the pharmaceutical composition of any of claims 74 to 79, thereby inhibiting the expression of the gene ANGPTL3 in the cell. Claim 100: A kit characterized in that it comprises the shRNA agent of any of claims 1 to 72 or the pharmaceutical composition of any of claims 74 to 79. Claim 101: A vial characterized in that it comprises the shRNA agent of any of claims 1 to 72 or the pharmaceutical composition of any of claims 74 to 79. Claim 102: A syringe characterized in that it comprises the shRNA agent of any of claims 1 to 72 or the pharmaceutical composition of any of claims 74 to 79.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163156476P | 2021-03-04 | 2021-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125021A1 true AR125021A1 (en) | 2023-05-31 |
Family
ID=86688892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100472A AR125021A1 (en) | 2021-03-04 | 2022-03-03 | RNAi COMPOSITIONS AGAINST THE ANGIOPOYETIN-LIKE GENE 3 (ANGPTL3) AND THEIR METHODS OF USE |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR125021A1 (en) |
-
2022
- 2022-03-03 AR ARP220100472A patent/AR125021A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20241132A1 (en) | ARNI COMPOSITIONS AND METHODS TO SILENCE ANGIOTENSINOGEN (AGT) | |
| AR125230A1 (en) | COMPOSITIONS OF ANTI-HUNTINGTIN (HTT) RNAi AGENTS AND THEIR METHODS OF USE | |
| PE20241933A1 (en) | COMPOSITIONS AND METHODS FOR INHIBITING ANGIOTENSINOGEN (AGT) PROTEIN EXPRESSION | |
| BR112015022876A2 (en) | agent, pharmaceutical composition and method for inhibiting expression of complement component c5, use of said agent, vector and cell. | |
| MX2021006745A (en) | CHEMICALLY MODIFIED IRNA CONSTRUCTS AND THEIR USES. | |
| AR090869A1 (en) | SERPINC1 RNAi COMPOSITIONS AND THEIR METHODS OF USE | |
| PE20210921A1 (en) | ARNI AGENTS AS INHIBITORS OF SERPINE 1 TRANSCRIPTION AND COMPOSITIONS THAT INCLUDE THEM | |
| MX2023008469A (en) | Modified double stranded oligonucleotides. | |
| AR120341A1 (en) | COMPOSITIONS OF RNAi AGENTS AGAINST HUNTINGTINE (HTT) AND THEIR METHODS OF USE | |
| AR123679A1 (en) | RNAi COMPOSITIONS AGAINST THE SNCA GENE AND METHODS OF USE THEREOF TO TREAT OR PREVENT NEURODEGENERATIVE DISEASES ASSOCIATED WITH SNCA | |
| AR127477A1 (en) | COMPOSITIONS OF RNAi AGAINST COMPLEMENT FACTOR B (CFB) AND METHODS OF USE THEREOF | |
| CR20240346A (en) | COMPOSITIONS AND METHODS FOR INHIBITING COMPLEMENT FACTOR B | |
| PE20250074A1 (en) | COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF MITOCHONDRIAL AMIDOXIME REDUCTION COMPONENT 1 (MARC1) | |
| MX2023012385A (en) | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF COMPONENT 3 OF THE COMPLEMENT. | |
| MX2025003172A (en) | Specifically modified rnai reagent and composition | |
| AR126070A1 (en) | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING STARGARDT DISEASE AND/OR DISORDERS ASSOCIATED WITH RETINOL BORDER PROTEIN 4 (RBP4) | |
| AR126771A1 (en) | RNAi COMPOSITIONS AGAINST FACTOR XII (F12) AND THEIR METHODS OF USE | |
| AR125021A1 (en) | RNAi COMPOSITIONS AGAINST THE ANGIOPOYETIN-LIKE GENE 3 (ANGPTL3) AND THEIR METHODS OF USE | |
| AR079649A1 (en) | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF GENES IL-18 | |
| AR124052A1 (en) | RNAi COMPOSITIONS AGAINST FACTOR V COAGULATION (F5) AND METHODS OF USE THEREOF | |
| WO2020139866A3 (en) | Compositions and methods for treating cancer | |
| AR130702A1 (en) | PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USING THE SAME | |
| AR127472A1 (en) | COMPOSITIONS OF RNAi AGENTS AGAINST HUNTINGTIN (HTT) AND THEIR METHODS OF USE | |
| AR126536A1 (en) | COMPOSITIONS OF RNAi DIRECTED AGAINST b-CATENIN (CTNNB1) AND THEIR METHODS OF USE | |
| AR125019A1 (en) | RNAi COMPOSITIONS AGAINST KETOHEXOKINASE (KHK) AND THEIR METHODS OF USE |